Associations of genetic variants in the transcriptional coactivators EP300 and PCAF with hepatocellular carcinoma

Cancer Epidemiology

Volumn 36, Issue 5, 2012, Pages

  Akil, Abdellah ^a,d   Ezzikouri, Sayeh ^a   El Feydi, Abdellah Essaid ^b   Benazzouz, Mustapha ^b   Afifi, Rajaa ^b   Diagne, Ama Gassama ^c   Benjouad, Aziz ^d   Dejean, Anne ^e   Pineau, Pascal ^e   Benjelloun, Soumaya ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

^c INSERM   (France)

^d MOHAMMED V UNIVERSITY   (Morocco)

^e INSTITUT PASTEUR   (France)

Author keywords

EP300; Genetic susceptibility; Histone acetyltransferases; Liver cancer; PCAF

Indexed keywords

E1A ASSOCIATED P300 PROTEIN; HISTONE ACETYLTRANSFERASE PCAF;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; EP300 GENE; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOROCCO; PCAF GENE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHROMOSOMAL INSTABILITY; E1A-ASSOCIATED P300 PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED; MOROCCO; MUTATION, MISSENSE; ODDS RATIO; P300-CBP TRANSCRIPTION FACTORS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS;

EID: 84865861864     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2012.05.011     Document Type: Article

References (46)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2(9):533-543.
2. McGlynn K.A., London W.T. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005, 19(1):3-23.
3. Eckner R., Ewen M.E., Newsome D., Gerdes M., DeCaprio J.A., Lawrence J.B., et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994, 8(8):869-884.
4. Giordano A., Avantaggiati M.L. p300 and CBP: partners for life and death. J Cell Physiol 1999, 181(2):218-230.
5. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384(6610):641-643.
6. Ogryzko V.V., Schiltz R.L., Russanova V., Howard B.H., Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87(5):953-959.
7. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997, 389(6649):349-352.
8. Kawasaki H., Eckner R., Yao T.P., Taira K., Chiu R., Livingston D.M., et al. Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature 1998, 393(6682):284-289.
9. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998, 93(3):361-372.
10. Hanstein B., Eckner R., DiRenzo J., Halachmi S., Liu H., Searcy B., et al. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci U S A 1996, 93(21):11540-11545.
11. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., et al. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 2000, 49(4):539-547.
12. Jacobson S., Pillus L. Modifying chromatin and concepts of cancer. Curr Opin Genet Dev 1999, 9(2):175-184.
13. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999, 9(1):40-48.
14. Grossman S.R., Deato M.E., Brignone C., Chan H.M., Kung A.L., Tagami H., et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003, 300(5617):342-344.
15. Grossman S.R., Perez M., Kung A.L., Joseph M., Mansur C., Xiao Z.X., et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998, 2(4):405-415.
16. Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997, 89(7):1175-1184.
17. Espinosa J.M., Emerson B.M. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001, 8(1):57-69.
18. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387(6635):823-827.
19. Wang X., Pan L., Feng Y., Wang Y., Han Q., Han L., et al. P300 plays a role in p16(INK4a) expression and cell cycle arrest. Oncogene 2008, 27(13):1894-1904.
20. Coutts A.S., La Thangue N.B. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 2005, 331(3):778-785.
21. Yang X.J., Ogryzko V.V., Nishikawa J., Howard B.H., Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382(6589):319-324.
22. Puri P.L., Sartorelli V., Yang X.J., Hamamori Y., Ogryzko V.V., Howard B.H., et al. Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997, 1(1):35-45.
23. Blanco J.C., Minucci S., Lu J., Yang X.J., Walker K.K., Chen H., et al. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 1998, 12(11):1638-1651.
24. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279(5351):703-707.
25. Xu L., Lavinsky R.M., Dasen J.S., Flynn S.E., McInerney E.M., Mullen T.M., et al. Signal-specific co-activator domain requirements for Pit-1 activation. Nature 1998, 395(6699):301-306.
26. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T., et al. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol 2006, 26(18):6859-6869.
27. Cohen H.Y., Lavu S., Bitterman K.J., Hekking B., Imahiyerobo T.A., Miller C., et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004, 13(5):627-638.
28. Martinez-Balbas M.A., Bauer U.M., Nielsen S.J., Brehm A., Kouzarides T. Regulation of E2F1 activity by acetylation. EMBO J 2000, 19(4):662-671.
29. Gregoire S., Xiao L., Nie J., Zhang X., Xu M., Li J., et al. Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol 2007, 27(4):1280-1295.
30. Wong K., Zhang J., Awasthi S., Sharma A., Rogers L., Matlock E.F., et al. Nerve growth factor receptor signaling induces histone acetyltransferase domain-dependent nuclear translocation of p300/CREB-binding protein-associated factor and hGCN5 acetyltransferases. J Biol Chem 2004, 279(53):55667-55674.
31. Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L., et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90(3):569-580.
32. Ezzikouri S., El Feydi A.E., Afifi R., Benazzouz M., Hassar M., Pineau P., et al. Polymorphisms in antioxidant defence genes and susceptibility to hepatocellular carcinoma in a Moroccan population. Free Radic Res 2010, 44(2):208-216.
33. Ezzikouri S., El Feydi A.E., Afifi R., El Kihal L., Benazzouz M., Hassar M., et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009, 32(5-6):380-385.
34. Ezzikouri S., El Feydi A.E., Benazzouz M., Afifi R., El Kihal L., Hassar M., et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 2009, 9(5):877-881.
35. Ezzikouri S., El Feydi A.E., Chafik A., Afifi R., El Kihal L., Benazzouz M., et al. Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res 2008, 649(1-2):1-6.
36. Ezzikouri S., El Feydi A.E., Chafik A., Benazzouz M., El Kihal L., Afifi R., et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 2007, 37(9):748-754.
37. Pineau P., Ezzikouri S., Marchio A., Benazzouz M., Cordina E., Afifi R., et al. Genomic stability prevails in North-African hepatocellular carcinomas. Dig Liver Dis 2007, 39(7):671-677.
38. Haiman C.A., Garcia R.R., Hsu C., Xia L., Ha H., Sheng X., et al. Screening and association testing of common coding variation in steroid hormone receptor co-activator and co-repressor genes in relation to breast cancer risk: the Multiethnic Cohort. BMC Cancer 2009, 9(43).
39. Wirtenberger M., Tchatchou S., Hemminki K., Schmutzhard J., Sutter C., Schmutzler R.K., et al. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis 2006, 27(11):2201-2208.
40. Nishimori H., Nishikawa R., Fujimaki T., Nakagomi T., Matsutani M., Huang H.J., et al. Analysis of the p300/CBP-Associated Factor (PCAF) gene in astrocytic tumors. J Neurooncol 2000, 46(1):17-22.
41. Kurdistani S.K. Histone modifications in cancer biology and prognosis. Prog Drug Res 2010, 67:91-106.
42. Sawan C., Herceg Z. Histone modifications and cancer. Adv Genet 2010, 70:57-85.
43. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003, 13(9):2129-2141.
44. Zondervan K.T., Cardon L.R. The complex interplay among factors that influence allelic association. Nat Rev Genet 2004, 5(2):89-100.
45. Robert J. Gene polymorphisms. Bull Cancer 2010, 97(11):1253-1264.
46. Castello G., Scala S., Palmieri G., Curley S.A., Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin Immunol 2010, 134(3):237-250.